Skip to main content
. 2021 May 6;4(5):e218065. doi: 10.1001/jamanetworkopen.2021.8065

Figure 1. Tornado Diagrams of Univariable Sensitivity Analyses.

Figure 1.

The diagram shows the association of variables with the incremental cost-effectiveness ratio (ICER) of nivolumab vs pembrolizumab in the treatment of platinum-refractory recurrent or metastatic head and neck squamous cell carcinoma. The vertical black line represents the primary result of $86 983 per quality-adjusted life-year (QALY) as the ICER in the base-case analysis. The vertical dotted lines represent the $100 000 and $150 000 per QALY willingness-to-pay thresholds used in the analysis. At the lower limit of the body weight (50 kg), the ICER was −$36 606 per QALY; at the upper limit of the body weight (90 kg), the ICER was $210 572 per QALY. BSC indicates best supportive care; HR, hazard ratio; PD, progressive disease; and PFS, progression-free survival.